chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Company profile
Ticker
KDNY
Exchange
Website
CEO
Stephen Isaacs
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADURO BIOTECH, ADURO BIOTECH, INC.
SEC CIK
Corporate docs
Subsidiaries
Chinook Therapeutics U.S, Inc. • Chinook Therapeutics Canada, Inc. • Aduro Biotech Holdings, Europe B.V. • Aduro Biotech Europe B.V. ...
KDNY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Aug 23
EFFECT
Notice of effectiveness
17 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Aug 23
Latest ownership filings
SC 13D/A
Samsara BioCapital, L.P.
22 Nov 23
SC 13D
Farallon Capital Partners, L.P.
11 Aug 23
4
Dolca Thomas
11 Aug 23
4
Andrew Oxtoby
11 Aug 23
4
Mahesh Krishnan
11 Aug 23
4
Andrew James King
11 Aug 23
4
MICHELLE RENEE GRIFFIN
11 Aug 23
4
William Mariner Greenman
11 Aug 23
4
Tom Frohlich
11 Aug 23
4
ERIC DOBMEIER
11 Aug 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 129.22 mm | 129.22 mm | 129.22 mm | 129.22 mm | 129.22 mm | 129.22 mm |
Cash burn (monthly) | (no burn) | 1.56 mm | 24.21 mm | 20.97 mm | 20.40 mm | 14.50 mm |
Cash used (since last report) | n/a | 15.40 mm | 238.23 mm | 206.35 mm | 200.74 mm | 142.69 mm |
Cash remaining | n/a | 113.82 mm | -109.01 mm | -77.13 mm | -71.51 mm | -13.47 mm |
Runway (months of cash) | n/a | 72.7 | -4.5 | -3.7 | -3.5 | -0.9 |
Institutional ownership, Q3 2023
17.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 183 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 327.26 mm |
Total shares | 12.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Farallon Capital Partners | 6.55 mm | $263.29 mm |
Frazier Life Sciences Public Fund | 3.13 mm | $0.00 |
Versant Venture Capital VII | 2.11 mm | $48.31 mm |
Vivo Capital IX | 987.62 k | $15.66 mm |
Samsara BioCapital | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Aug 23 | Akkaraju Srinivas | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 5,161,888 | 0.00 | 0 |
11 Aug 23 | Akkaraju Srinivas | Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,300 | 0.00 | 0 |
11 Aug 23 | Akkaraju Srinivas | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 26.12 | 13,300 | 347.40 k | 0 |
11 Aug 23 | Akkaraju Srinivas | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 23.19 | 5,948 | 137.93 k | 0 |
11 Aug 23 | Akkaraju Srinivas | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 25.23 | 23,522 | 593.46 k | 0 |
11 Aug 23 | Azelby Robert | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,000 | 0.00 | 0 |
11 Aug 23 | Azelby Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 18.4 | 28,200 | 518.88 k | 0 |
11 Aug 23 | Eric Bjerkholt | Common Stock | Sale back to company | Dispose D | No | No | 0 | 39,371 | 0.00 | 0 |
11 Aug 23 | Eric Bjerkholt | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 8,400 | 0.00 | 0 |
11 Aug 23 | Eric Bjerkholt | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 21,000 | 0.00 | 0 |